Nanobiotix is trading 5.7% lower at $22.06 on October 13, 2026, amid biotech weakness, but no clear company-specific catalyst has emerged. - The supplied sector snapshot shows XBI down 2.01%, less than Nanobiotix’s decline. - The CFO appointment reported October 13 took effect October 1, so it was not a new-day catalyst. - Recent reporting describes a broader biotech sentiment pullback and ongoing Nanobiotix sell-off without a clear catalyst, leaving today’s sharper decline unexplained.